Addex Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of allosteric modulators for G protein-coupled receptors (GPCRs). Its research platform leverages novel medicinal chemistry approaches to identify compounds that adjust receptor activity in a finely tuned manner, with the aim of delivering safer and more effective therapies for central nervous system (CNS) disorders. The company’s lead programs target indications such as Parkinson’s disease, ataxia and essential tremor, where there remains a significant unmet medical need.
The company’s pipeline includes small-molecule candidates designed to modulate metabotropic glutamate receptors (mGluRs), with an emphasis on leveraging allosteric sites to achieve greater receptor subtype selectivity. Among its most advanced programs is a selective mGlu4 positive allosteric modulator for the treatment of motor symptoms in Parkinsonian conditions, which has progressed through early-stage clinical trials. Preclinical assets in its portfolio are directed at mGlu2 and mGlu7 receptors, reflecting Addex’s commitment to expanding its therapeutic reach across multiple neurological and psychiatric indications.
Founded and headquartered in Geneva, Switzerland, Addex maintains research collaborations and strategic partnerships in both Europe and North America. The company’s state-of-the-art laboratories in Geneva are complemented by business development and regulatory affairs offices in the United States, enabling Addex to engage closely with regulatory agencies such as the U.S. FDA and the European Medicines Agency. Over the years, the company has entered collaboration agreements with leading pharmaceutical firms to co-develop and out-license key assets.
The leadership team at Addex is composed of seasoned executives and scientists with deep expertise in neuroscience, drug discovery and clinical development. Supported by a board of directors with backgrounds in global pharma and biotech, the management group has guided the company’s growth from a university spin-out to a publicly traded enterprise focused on delivering next-generation therapies for CNS disorders. Addex’s global footprint and experienced leadership position it to advance its innovative pipeline through the clinic and toward potential partnerships or commercialization.
AI Generated. May Contain Errors.
